SCHEMBL3778014

SCHEMBL3778014

COC(=O)COc1ccc(Cl)c2[nH]c(C)c(Cc3ccc(Cl)cc3)c(=O)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
SLC2A1 P11166 1/20 0.38
PTGDR Q13258 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
PTGS2 P35354 2/20 0.37
LPAR2 Q9HBW0 1/20 0.36
TSHR P16473 2/20 0.36
GAA P10253 2/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPT P10636 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HPGD P15428 2/20 0.34
MAPK1 P28482 2/20 0.34
PLA2G2A P14555 1/20 0.34
PTGS1 P23219 1/20 0.34
ALOX15 P16050 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788309 0.92 MAPT (0.41) LMNASLC2A1TSHRGAAHTT
SCHEMBL3783224 0.91 SLC2A1 (0.43) LMNASLC2A1PTGDRPTGDR2PTGS2
SCHEMBL3780994 0.90 TSHR (0.42) LMNAPTGDR2PTGS2TSHRGAA
SCHEMBL3779072 0.88 LMNA (0.37) LMNAPTGDRPTGDR2PTGS2TSHR
SCHEMBL3778704 0.86 LMNA (0.38) LMNAPTGDRPTGDR2PTGS2LPAR2
SCHEMBL3779598 0.82 TYMS (0.40) LMNAPTGDRPTGDR2PTGS2LPAR2
SCHEMBL3772920 0.80 TSHR (0.42) LMNAPTGDR2PTGS2TSHRGAA
SCHEMBL3777589 0.80 TSHR (0.40) LMNAPTGDR2PTGS2TSHRGAA
SCHEMBL3772034 0.80 GAA (0.39) LMNAPTGDR2PTGS2TSHRGAA
SCHEMBL3779428 0.79 PTGDR2 (0.36) LMNASLC2A1PTGDRPTGDR2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 LMNA 3732/4885SLC2A1 3121/4885PTGDR 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.